Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jingwei Xu

Showing results (151-160 of 151) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 151 results.
The Lancet. Oncology|May 14, 2023
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialPin Zhang, Qingyuan Zhang, Zhongsheng Tong, et al.
Pageof 16

Showing results (151-160 of 151) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 151 results.
The Lancet. Oncology|May 14, 2023
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trialPin Zhang, Qingyuan Zhang, Zhongsheng Tong, et al.
Pageof 16